Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.55 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.54 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.54 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL241514 | 1.00 | ALDH1A1 (0.58) | ALDH1A1DPP4F2ADRA2AADRA2C | |
| Hydrochloric Acid SCHEMBL4381111 | 1.00 | ALDH1A1 (0.58) | ALDH1A1DPP4F2ADRA2AADRA2C | |
| Hydrochloric Acid SCHEMBL4602345 | 1.00 | ALDH1A1 (0.58) | ALDH1A1DPP4F2ADRA2AADRA2C | |
| Hydrochloric Acid SCHEMBL4381169 | 1.00 | ALDH1A1 (0.58) | ALDH1A1DPP4F2ADRA2AADRA2C | |
| Hydrochloric Acid SCHEMBL27370227 | 0.97 | ALDH1A1 (0.56) | ALDH1A1DPP4F2ADRA2AADRA2C | |
| SCHEMBL24932018 | 0.97 | DPP4 (0.58) | ALDH1A1DPP4F2ADRA2AADRA2C | |
| SCHEMBL830 | 0.97 | — | — | |
| SCHEMBL5559781 | 0.97 | DPP4 (0.58) | ALDH1A1DPP4F2ADRA2AADRA2C | |
| SCHEMBL4916236 | 0.97 | DPP4 (0.58) | ALDH1A1DPP4F2ADRA2AADRA2C | |
| SCHEMBL5565016 | 0.97 | DPP4 (0.58) | ALDH1A1DPP4F2ADRA2AADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0672030-B1 | PROCESS FOR PREPARING SUBSTANTIALLY PURE ENANTIOMERS OF PHENYLPROPIONIC ACIDS | KNOLL AG (DE) | 1997-04-16 | — | — | EP | claimed |
| US-5599969-A | PURIFICATION BY SALT FORMATION AND DESALTING | THE BOOTS COMPANY PLC (GB) | 1997-02-04 | — | — | US | claimed |
| EP-0714292-A4 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE INC (US) | 1996-10-09 | — | — | EP | claimed |
| EP-0714292-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-06-05 | — | — | EP | claimed |
| WO-1995000131-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE, INCORPORATED (US) | 1995-01-05 | — | — | WO | claimed |
| CN-110078736-B | Pyrazolopyrimidine derivative, process for producing the same, and use thereof | 广州白云山医药集团股份有限公司白云山制药总厂 | 2021-08-03 | — | — | CN | disclosed |
| CN-110078736-A | Pyrazolopyrimidine derivative, preparation method and its application | 广州白云山医药集团股份有限公司白云山制药总厂 | 2019-08-02 | — | — | CN | disclosed |
| US-9452974-B2 | Stereoselective synthesis of metyrosine | ATON PHARMA, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| CN-103804199-B | Synthesis method of chiral alpha-phenylethylamine hydrochloride | LUO MEI (CN) | 2016-04-13 | — | — | CN | disclosed |
| US-20140350284-A1 | STEREOSELECTIVE SYNTHESIS OF METYROSINE | JPMORGAN CHASE BANK, N.A. | 2014-11-27 | — | — | US | disclosed |
| US-8841486-B2 | Stereoselective synthesis of metyrosine | ATON PHARMA (US) | 2014-09-23 | — | — | US | disclosed |
| CN-103804199-A | Synthetic method of chiral alpha-phenylethylamine hydrochloride | LUO MEI | 2014-05-21 | — | — | CN | disclosed |
| US-5599969-A | PURIFICATION BY SALT FORMATION AND DESALTING | THE BOOTS COMPANY PLC (GB) | 1997-02-04 | — | — | US | disclosed |
| EP-0672030-A1 | PROCESS FOR PREPARING SUBSTANTIALLY PURE ENANTIOMERS OF PHENYLPROPIONIC ACIDS. | BOOTS CO PLC (GB) | 1995-09-20 | — | — | EP | disclosed |
| US-5349079-A | Process for forming α-aminonitriles from carbonyl compound and fatty amine hydrohalide | AKZO NOBEL NV (NL) | 1994-09-20 | — | — | US | disclosed |
| US-5340802-A | Central nervous system disorders | ABBOTT LABORATORIES (US) | 1994-08-23 | — | — | US | disclosed |
| WO-1994012460-A1 | PROCESS FOR PREPARING SUBSTANTIALLY PURE ENANTIOMERS OF PHENYLPROPIONIC ACIDS | THE BOOTS COMPANY PLC (GB) | 1994-06-09 | — | — | WO | disclosed |
| US-5288747-A | Method of controlling or preventing phytopathogenic microorganism infestation of plants using propiconazole as a seed dressing | CIBA-GEIGY CORPORATION (US) | 1994-02-22 | — | — | US | disclosed |
| WO-1991000724-A1 | ALKYNYL AMINES THAT REGULATE CHOLINERGIC NEUROTRANSMISSION | ABBOTT LABORATORIES (US) | 1991-01-24 | — | — | WO | disclosed |
| US-4940799-A | Preparation of the diastereomeric mixture 2R,4S-1-[2-(2,4-dichlorophenyl)-4-n-propyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole | CIBA-GEIGY CORPORATION (US) | 1990-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350284-A1 | STEREOSELECTIVE SYNTHESIS OF METYROSINE | PTMA, PTMS, METTL3 | DPP4 469/4885ADRA2A 100/4885ADRA2C 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.